Abstract

Schizophrenia is a group of severe mental disorders. ZBTB20 is critical in brain development and corticogenesis and its dysfunction induces various neural disorders. ERK/CREB signalling is a potential downstream pathway of ZBTB20. Up-regulated microRNA-144-3p (miR-144-3p) were found in schizophrenic model rats in our previous study. This study investigated whether suppressed ZBTB20/ERK/CREB1 signalling caused by up-regulated miR-144-3p is associated with schizophrenia-like abnormalities in animals. A MK-801 rat model was established by 2-week MK-801 administration. An RNA-Seq test was performed to reveal differentially expressed genes in model rat hippocampus (HIP). MiR-144-3p-overexpressed SK-N-SH and 293T cell models were constructed by lentivirus, respectively. The in vitro and in vivo levels of miR-144-3p and ZBTB20, and the activation of the ERK/CREB1 signalling were examined by qRT-PCR, Western blots, or immunohistochemistry. The interaction between miR-144-3p and ZBTB20 was predicted and assessed by using bioinformatic methods and a luciferase reporter gene assay on 293T cells, respectively. The RNA-Seq test revealed that ZBTB20 was altered in the model rat HIP. Further experiments confirmed the reduced ZBTB20 mRNA and protein levels in the model rat HIP and caudate putamen (CPu), accompanied by increased miR-144-3p levels. Moreover, the ZBTB20 expression and ERK/CREB1 phosphorylation was decreased in the miR-144-3p-overexpressed 293T cells. These abnormal changes in the ZBTB20 expression and ERK/CREB1 phosphorylation levels were also observed in the model rat brain, but could be reversed by risperidone. In conclusion, this study revealed that dysfunctional miR-144-3p/ZBTB20/ERK/CREB1 signalling might be associated with schizophrenia-like abnormalities, suggesting potential therapeutic targets for future schizophrenia treatment.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.